Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
for Major Depressive Disorder (MDD)
21 locations incl. Phoenix
Sponsor: Vanda Pharmaceuticals
Sex: All·Age: 18 - 65
Code: NCT06830044·Phase 3·Recruiting